PubMed:29223722 JSONTXT

{"project":"Zierdiyeerkenaili_800","denotations":[{"id":"T1","span":{"begin":33,"end":42},"obj":"CI"},{"id":"T2","span":{"begin":1447,"end":1456},"obj":"CI"},{"id":"T3","span":{"begin":63,"end":88},"obj":"DP"},{"id":"T4","span":{"begin":596,"end":605},"obj":"CI"},{"id":"T5","span":{"begin":264,"end":273},"obj":"CI"},{"id":"T6","span":{"begin":660,"end":669},"obj":"CI"},{"id":"T7","span":{"begin":686,"end":695},"obj":"CI"},{"id":"T8","span":{"begin":1252,"end":1261},"obj":"CI"},{"id":"T9","span":{"begin":1703,"end":1712},"obj":"CI"},{"id":"T10","span":{"begin":1768,"end":1771},"obj":"DP"},{"id":"T11","span":{"begin":231,"end":234},"obj":"DP"},{"id":"T12","span":{"begin":1007,"end":1010},"obj":"DP"},{"id":"T13","span":{"begin":1136,"end":1139},"obj":"DP"},{"id":"T14","span":{"begin":1307,"end":1310},"obj":"DP"},{"id":"T15","span":{"begin":1378,"end":1381},"obj":"DP"},{"id":"T16","span":{"begin":1477,"end":1480},"obj":"DP"},{"id":"T17","span":{"begin":204,"end":229},"obj":"DP"}],"text":"The Effectiveness of Intravenous Parecoxib on the Incidence of Ipsilateral Shoulder Pain After Thoracotomy: A Randomized, Double-Blind, Placebo-Controlled Trial.\nOBJECTIVES: To determine the incidence of ipsilateral shoulder pain (ISP) with the therapeutic use of parecoxib compared with a placebo after thoracotomy.\nDESIGN: A prospective, randomized, double-blind, placebo-controlled trial.\nSETTING: A tertiary-care university hospital.\nPARTICIPANTS: Adult patients undergoing an elective thoracotomy between June 2011 and February 2015.\nINTERVENTIONS: Patients were allocated randomly into the parecoxib group (n = 80) and the control group (n = 80). In the parecoxib group, 40 mg of parecoxib was diluted into 2 mL and given intravenously 30 minutes before surgery and then every 12 hours postoperatively for 48 hours. In the control group, 2 mL of normal saline was given to the patients at the same intervals.\nMEASUREMENTS AND MAIN RESULTS: A numerical rating scale was used to assess the intensity of ISP at 2, 6, 12, 24, 48, 72, and 96 hours after surgery. Intravenous morphine (0.05 mg/kg) was used as the rescue medication for ISP during the 96-hour period. Baseline characteristics of patients in both groups were comparable. Patients in the parecoxib group had a significantly lower incidence of ISP, both overall (42.5% v 62.0%, p = 0.014) and of moderate-to-severe ISP when compared with the control group (26.2% v 49.4%, p = 0.003). Parecoxib reduced the risk of ISP by a statistically significant 32% (risk ratio, 0.68; 95% confidence interval, 0.50-0.93, p = 0.016). There were no significant differences in the occurrence of adverse effects between the groups.\nCONCLUSIONS: Intravenous parecoxib significantly can reduce the incidence and severity of ISP after thoracotomy."}

{"project":"Linmchun_800_3","denotations":[{"id":"T1","span":{"begin":33,"end":42},"obj":"CI"},{"id":"T2","span":{"begin":264,"end":273},"obj":"CI"},{"id":"T3","span":{"begin":660,"end":669},"obj":"CI"},{"id":"T4","span":{"begin":596,"end":605},"obj":"CI"},{"id":"T5","span":{"begin":686,"end":695},"obj":"CI"},{"id":"T6","span":{"begin":859,"end":865},"obj":"CI"},{"id":"T7","span":{"begin":1252,"end":1261},"obj":"CI"},{"id":"T8","span":{"begin":1447,"end":1456},"obj":"CI"},{"id":"T9","span":{"begin":1703,"end":1712},"obj":"CI"}],"text":"The Effectiveness of Intravenous Parecoxib on the Incidence of Ipsilateral Shoulder Pain After Thoracotomy: A Randomized, Double-Blind, Placebo-Controlled Trial.\nOBJECTIVES: To determine the incidence of ipsilateral shoulder pain (ISP) with the therapeutic use of parecoxib compared with a placebo after thoracotomy.\nDESIGN: A prospective, randomized, double-blind, placebo-controlled trial.\nSETTING: A tertiary-care university hospital.\nPARTICIPANTS: Adult patients undergoing an elective thoracotomy between June 2011 and February 2015.\nINTERVENTIONS: Patients were allocated randomly into the parecoxib group (n = 80) and the control group (n = 80). In the parecoxib group, 40 mg of parecoxib was diluted into 2 mL and given intravenously 30 minutes before surgery and then every 12 hours postoperatively for 48 hours. In the control group, 2 mL of normal saline was given to the patients at the same intervals.\nMEASUREMENTS AND MAIN RESULTS: A numerical rating scale was used to assess the intensity of ISP at 2, 6, 12, 24, 48, 72, and 96 hours after surgery. Intravenous morphine (0.05 mg/kg) was used as the rescue medication for ISP during the 96-hour period. Baseline characteristics of patients in both groups were comparable. Patients in the parecoxib group had a significantly lower incidence of ISP, both overall (42.5% v 62.0%, p = 0.014) and of moderate-to-severe ISP when compared with the control group (26.2% v 49.4%, p = 0.003). Parecoxib reduced the risk of ISP by a statistically significant 32% (risk ratio, 0.68; 95% confidence interval, 0.50-0.93, p = 0.016). There were no significant differences in the occurrence of adverse effects between the groups.\nCONCLUSIONS: Intravenous parecoxib significantly can reduce the incidence and severity of ISP after thoracotomy."}

{"project":"luoyt2021_800_3","denotations":[{"id":"T1","span":{"begin":33,"end":42},"obj":"CI"},{"id":"T2","span":{"begin":1703,"end":1712},"obj":"CI"},{"id":"T3","span":{"begin":1447,"end":1456},"obj":"CI"},{"id":"T4","span":{"begin":1252,"end":1261},"obj":"CI"},{"id":"T5","span":{"begin":686,"end":695},"obj":"CI"},{"id":"T6","span":{"begin":660,"end":669},"obj":"CI"},{"id":"T7","span":{"begin":596,"end":605},"obj":"CI"},{"id":"T8","span":{"begin":264,"end":273},"obj":"CI"},{"id":"T9","span":{"begin":859,"end":865},"obj":"CI"}],"text":"The Effectiveness of Intravenous Parecoxib on the Incidence of Ipsilateral Shoulder Pain After Thoracotomy: A Randomized, Double-Blind, Placebo-Controlled Trial.\nOBJECTIVES: To determine the incidence of ipsilateral shoulder pain (ISP) with the therapeutic use of parecoxib compared with a placebo after thoracotomy.\nDESIGN: A prospective, randomized, double-blind, placebo-controlled trial.\nSETTING: A tertiary-care university hospital.\nPARTICIPANTS: Adult patients undergoing an elective thoracotomy between June 2011 and February 2015.\nINTERVENTIONS: Patients were allocated randomly into the parecoxib group (n = 80) and the control group (n = 80). In the parecoxib group, 40 mg of parecoxib was diluted into 2 mL and given intravenously 30 minutes before surgery and then every 12 hours postoperatively for 48 hours. In the control group, 2 mL of normal saline was given to the patients at the same intervals.\nMEASUREMENTS AND MAIN RESULTS: A numerical rating scale was used to assess the intensity of ISP at 2, 6, 12, 24, 48, 72, and 96 hours after surgery. Intravenous morphine (0.05 mg/kg) was used as the rescue medication for ISP during the 96-hour period. Baseline characteristics of patients in both groups were comparable. Patients in the parecoxib group had a significantly lower incidence of ISP, both overall (42.5% v 62.0%, p = 0.014) and of moderate-to-severe ISP when compared with the control group (26.2% v 49.4%, p = 0.003). Parecoxib reduced the risk of ISP by a statistically significant 32% (risk ratio, 0.68; 95% confidence interval, 0.50-0.93, p = 0.016). There were no significant differences in the occurrence of adverse effects between the groups.\nCONCLUSIONS: Intravenous parecoxib significantly can reduce the incidence and severity of ISP after thoracotomy."}